Trillium Therapeutics Inc

Phase 1

Drug: TTI-1612
 

NCT01559961

Study Completion Date : March 2013

Safety Study of Single Intravesical Doses of TTI-1612 in Women With Interstitial Cystitis/Bladder Pain Syndrome.